Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Subscribe To Our Newsletter & Stay Updated